Search Results
Sep 10, 2026, 10:05 ET Immuno-Oncology Pioneer Dr. Michael Kalos Joins Kos Biotechnology Partners as Venture Partner
Biotechnology Partners, a global life sciences investment firm, today announced the appointment of renowned immuno-oncology leader Michael Kalos, PhD, as Venture Partner. Dr. Kalos brings decades of biopharmaceutical executive leadership, drug discovery, translational medicine, and venture creation
More news about: Kos Biotechnology Partners
Sep 10, 2026, 09:11 ET Nootropics Depot Sponsors Future Nutra Innovation Summit
(COAs), and lab testing results available on every product page. In addition, they have formed a Scientific Advisory Board with board certified doctors, PhD researchers, and botanists to ensure that consumers can trust that scientific rigor is being upheld in everything they do. Nootropics Depot's newly redesigned
More news about: Nootropics Depot
Sep 10, 2026, 09:02 ET Neurophos Scales Team and Opens Silicon Valley Office to Accelerate Commercialization
recently CEO of Redered.ai, a synthetic data platform for training artificial intelligence systems. Nathan has a Master's in Electrical Engineering and a PhD in Physics from Duke University. He also founded Intellectual Ventures' Center for Metamaterials.Dr. Michael Shebanow - SVP of EngineeringDr.
More news about: Neurophos
Sep 10, 2026, 09:00 ET NEURELIS CEO CRAIG CHAMBLISS TO PRESENT KEYNOTE AT THE 14TH ANNUAL OUTSOURCING IN CLINICAL TRIALS SOUTHERN CALIFORNIA 2026 CONFERENCE
Prescribing Information, including Boxed Warning.Contacts: Marie Rossi, PhD, Public and Investor Relations, [email protected], +1 858 251 2100
More news about: Neurelis, Inc.
Sep 10, 2026, 08:49 ET GBI Bio Appoints Jesse McCool, Ph.D., as Chief Executive Officer
multimedia:https://www.prnewswire.com/news-releases/gbi-bio-appoints-jesse-mccool-phd-as-chief-executive-officer-302874729.htmlSOURCE
More news about: GBI Biomanufacturing
Sep 10, 2026, 08:30 ET Good Clean Clinical Care Launches Microbiome-First Telehealth Platform for Women's Health
puts our growing understanding of the vaginal microbiome into practice, creating a stronger foundation for more personalized care," said Kim Capone, PhD, Chief Scientific Officer at GCCC and lead researcher of the VENUS Study.Good Clean Clinical Care is now available at
More news about: Good Clean Clinical Care
Sep 10, 2026, 08:30 ET Zifo Co-Launches REAL 2026 to Spotlight the Next Generation of Connected, AI-Enabled Lab Environments
LILAClosing Panel: What Will It Actually Take to Make It REAL?Moderated by Stacie Calad-Thomson, PhD, Global Business Development Lead, Pharma Labs and Manufacturing at NVIDIAAdvancing Readiness and Enablement for Automated
More news about: Zifo
Sep 10, 2026, 08:00 ET Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
treatment administration, and follow-up."This is a moment Fluence has been preparing for since our earliest days," said Elizabeth Nielson, PhD, Chief Executive Officer and Co-Founder of Fluence. "Our goal has always been to help clinicians translate rigorous psychedelic research into safe,
More news about: Fluence International, Inc.
Sep 10, 2026, 08:00 ET OncoHost to Present New PROphetNSCLC® Data at WCLC 2026 Demonstrating Predictive Performance Beyond Baseline Sampling
assay"."Immunotherapy is today the cornerstone of treatment for NSCLC patients without an oncogenic driving abnormality", added Fred Hirsch, MD, PhD, FASCO, Professor of Medicine & Pathology, Medical Oncologist, Clinical Advisor at OncoHost and co-author of the study. "The PROphet blood-based
More news about: OncoHost
Sep 10, 2026, 06:13 ET AI-Assisted Imaging Tool for Breast Cancer Could Tailor Screening for Women According to Individual Risk
Against Breast Cancer.Besides Drs. Xu, Shen, and Heacock, other study co-investigators were Jungkyu Park, PhD; Felicia Pasadyn, MA; Qi Lei, PhD; Alana Lewin, MD; Krzysztof Geras, PhD; Linda Moy, MD; and Freya Schnabel, MD.STUDY DOI10.2214/AJR.26.34951STUDY LINK
More news about: NYU Langone Health System
Sep 09, 2026, 20:30 ET Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
this breakthrough with higher speed and reduced cost, which could make a lot of difference in the future of drug discovery," said Carol Satler, MD, PhD, Senior Vice President for Clinical Development, Non-Oncology at Insilico Medicine. "With the first patient dosed, we hope to see real-world improvements
More news about: Insilico Medicine
Sep 09, 2026, 18:21 ET University of Phoenix Highlights Student Success Stories from President's and Dean's List Honorees
programs of study."Behind every President's and Dean's List recognition is a unique story of commitment, perseverance and purpose," said John Woods, PhD, provost and chief academic officer at University of Phoenix. "The student reflections shared through this initiative highlight the determination our
More news about: University of Phoenix
Sep 09, 2026, 15:39 ET Marquis Who's Who Honors Monib A. Zirvi, MD, PhD, for Excellence in Dermatology
Who's Who announces the inclusion of Monib A. Zirvi, MD, PhD, in its biographical volumes in recognition of his more than two decades of contributions to dermatology, medical research and patient care.
More news about: Marquis Who's Who
Sep 09, 2026, 14:19 ET Anatool Launches to Improve Recognition and Treatment of Anaphylaxis
and Clinical Immunology. Dribin co-chaired the work with Hugh Sampson, MD, of the Icahn School of Medicine at Mount Sinai, and Antonella Muraro, PhD, at the University of Padua. The tool translates those recommendations into an easy-to-use digital resource for busy clinical environments."Anaphylaxis
More news about: Cincinnati Children's Hospital Medical Center
Sep 09, 2026, 14:00 ET The Life You Can Save's 2026 Education Sector Report Finds 9 in 10 Children in Low-Income Countries Reach Age 10 Unable to Read
opportunity is not simply to put more resources into education, but to make sure those resources strengthen what already works," said Miriam Broeks, PhD, Research and Evaluation Manager at The Life You Can Save. "By investing in teachers, improving classroom instruction and strengthening the capacity
More news about: The Life You Can Save
Sep 09, 2026, 13:41 ET Oakwell Beer Spa Signs First Franchise Deal, Bringing Social Wellness Concept to Las Vegas
That's what drew us to Oakwell."Today, Andrew teaches Strategy & Implementation at UNLV's Harrah College of Hospitality while pursuing a PhD in Global Tourism & Hospitality. Gina brings experience across sales, marketing, operations, and entrepreneurship and currently serves as Founder
More news about: Oakwell Beer Spa
Sep 09, 2026, 13:02 ET Atman Health Wins ARPA-H Award to Build Agentic AI for Cardiovascular Care, Starting with Heart Failure
workforce does not exist.Rahul Deo, MD, PhD, co-founder, CMO and CPO"In heart failure, a single wrong adjustment can put a patient in the emergency department with elevated potassium, kidney injury or an arrhythmia," said Rahul Deo, MD, PhD, co-founder, chief product officer and chief
More news about: Atman Health, Inc.
Sep 09, 2026, 12:49 ET /C O R R E C T I O N -- Partillion Bioscience/
meaningful because it reflects the scientific merit of Cell-Cell-seq and gives us the resources to move the platform forward," said Joseph de Rutte, PhD, Co-Founder and CEO of Partillion Bioscience. "It allows us to pursue ambitious scientific work while keeping our private capital focused on customer
More news about: Partillion Bioscience
Sep 09, 2026, 12:38 ET /C O R R E C T I O N -- Altesa Biosciences Inc./
"Inflammatory biomarkers are reduced by vapendavir treatment in rhinovirus-challenged COPD patients," was presented by Dr. Sebastian Johnston, MD, PhD, FMedSci, Professor of Respiratory Medicine and Allergy at the National Heart and Lung Institute, Imperial College London, in a session titled: "Respiratory
More news about: Altesa Biosciences Inc.
Sep 09, 2026, 11:18 ET Feeding Mice Fewer Calories Reduces DNA Mutations
Gilad D. Evrony, MD, PhD, a core member of the
More news about: NYU Langone Health System
Sep 09, 2026, 11:02 ET Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer
Dammeijer, MD, PhD, Erasmus MC. "When we began this work, we were asking a straightforward question: how do cancer cells block effective anti-tumor immune responses where they are first generated, in the lymph node? The answer, unexpectedly, kept pointing to PLA2G2D."Ralph Stadhouders, PhD, Erasmus
More news about: Apeximmune
Sep 09, 2026, 11:00 ET More Than 400 Health Care Professionals to Gather in Illinois to Improve Patient Care
Catherine R. Lucey, MD, MACP, Executive Vice Chancellor and Provost, University of California, San Francisco Zirui Song, MD, PhD, Associate Professor of Health Care Policy and Medicine, Harvard Medical School and Massachusetts General Hospital; Member, Massachusetts
More news about: American Board of Medical Specialties
Sep 09, 2026, 10:06 ET Cronus Market Intelligence Publishes RegimeSignal's Accuracy Signal by Signal -- Bear 86%, Correction 84%, Pullback 83%, Recovery 82%, Averaging 84% Across the Full S&P 500 Cycle
historical upper bound and the signal the PhD reviews qualified.RegimeSignal also screens individual stocks, sectors and global indexes, and issues a report on any name covered. Those layers are coverage; the 84% covers the four S&P 500 signals only.The PhD reviews reproduced the bear, pullback
More news about: Cronus Market Intelligence, LLC
Sep 09, 2026, 09:04 ET Onix Expands Its Trusted AI Platform With $5 Million USD Pre-Seed Round
Elissa Epel, PhD; Nicole Beurkens, PhD;
More news about: Onix
Sep 09, 2026, 09:00 ET Mighty Therapeutics Initiates IND-Enabling Studies of MYTX-255: a Mitochondrial-Targeted Therapeutic Candidate
mitochondria-targeted therapeutic toward the clinic, furthering our pioneering work in mitochondrial medicine across a range of serious diseases," said David A. Brown, PhD, Chief Scientific Officer at Mighty Therapeutics. "Based on the compelling data we recently presented at the INFORM Annual Meeting, we intend to develop
More news about: Mighty Therapeutics